<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02219633</url>
  </required_header>
  <id_info>
    <org_study_id>LP0083-1085</org_study_id>
    <secondary_id>2014-000849-80</secondary_id>
    <nct_id>NCT02219633</nct_id>
  </id_info>
  <brief_title>Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)</brief_title>
  <official_title>An Explorative Trial Evaluating the Effect of LEO 39652 Cream in Adults With Mild to Moderate Atopic Dermatitis (AD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to assess the efficacy of LEO 39652 cream compared with LEO 39652
      cream vehicle in adults with mild to moderate AD after 3 weeks of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total sign score at end of treatment</measure>
    <time_frame>22 days</time_frame>
    <description>Total Sign Score is defined as the sum of severity scores (4-point scale) of the Individual Sign Scores(erythema, edema/papulation, oozing/crusting, excoriations, lichenification and dryness)for each assessed area.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total sign score on limited treatment area</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's treatment area assessment of disease severity</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject´s treatment area assessment of disease severity</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject´s assessment of itching</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transepidermal Water Loss</measure>
    <time_frame>22 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 39652 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 39652 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical application</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 39652 cream</intervention_name>
    <description>Applied for 21 days</description>
    <arm_group_label>LEO 39652 cream</arm_group_label>
    <arm_group_label>LEO 39652 cream vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with Atopic Dermatitis (AD) as defined by Hanifin and Rajka criteria and with
             mild to moderate disease severity (IGA 2 or 3)

          -  Two symmetrical and comparable Entire Treatment Areas, on the same body region (left
             and right part)

          -  Subjects must be in good health

          -  Female subjects of childbearing potential and male subjects must be willing to consent
             to using high effective methods of contraception

        Exclusion Criteria:

          -  Any condition in the treatment areas that in the opinion of the investigator could
             interfere with clinical assessments, e.g. acne, infection, rash (other than atopic
             dermatitis), sunburn, hyper-or hypopigmentation, scars

          -  Dark-skinned persons (i.e. skin type IV to VI according to Fitzpatrick classification
             system) whose skin colour prevents reliable clinical assessments

          -  Any permanent (or transient within 28 days prior to dosing) disease (in particular
             cardiac disease such as heart failure or history of myocardial infarction) that may
             interfere with the subjects safe participation in the trial, with the subjects ability
             to participate in the trial or with the clinical assessments

          -  Subjects with congenital or acquired immunodeficiencies or in subjects on therapy that
             causes immunosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lydia Graßhoff, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Proinnovera GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>proinnovera GmbH, Center of Dermatology Excellence</name>
      <address>
        <city>Münster</city>
        <zip>48159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.leo-pharma.com/Home/Research-and-Development/Clinical-trial-disclosure/Clinical-trial-summaries-and-reports.aspx</url>
    <description>Clinical Trials at LEO Pharma</description>
  </link>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2014</study_first_submitted>
  <study_first_submitted_qc>August 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>June 13, 2016</last_update_submitted>
  <last_update_submitted_qc>June 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

